Clarus Therapeutics (NASDAQ:CRXT) Given New $1.50 Price Target at Maxim Group

Clarus Therapeutics (NASDAQ:CRXTGet Rating) had its price target lowered by investment analysts at Maxim Group to $1.50 in a research note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s price objective would suggest a potential upside of 284.52% from the company’s current price.

A number of other equities research analysts also recently weighed in on CRXT. Truist Financial cut their target price on Clarus Therapeutics from $7.00 to $3.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. Needham & Company LLC cut their price objective on Clarus Therapeutics to $3.00 and set a “buy” rating for the company in a report on Tuesday, May 17th. Finally, Zacks Investment Research raised Clarus Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Monday, April 4th. Five equities research analysts have rated the stock with a buy rating, According to data from, the stock presently has an average rating of “Buy” and a consensus target price of $6.88.

Clarus Therapeutics stock traded up $0.02 during mid-day trading on Thursday, hitting $0.39. 185,348 shares of the company’s stock traded hands, compared to its average volume of 8,450,540. Clarus Therapeutics has a one year low of $0.35 and a one year high of $31.24. The firm has a 50 day moving average price of $1.00 and a 200 day moving average price of $2.00.

Clarus Therapeutics (NASDAQ:CRXTGet Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.61) earnings per share for the quarter. The company had revenue of $4.01 million for the quarter. On average, research analysts expect that Clarus Therapeutics will post -1.22 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Powell Investment Advisors LLC lifted its holdings in shares of Clarus Therapeutics by 48.8% during the fourth quarter. Powell Investment Advisors LLC now owns 64,000 shares of the company’s stock valued at $156,000 after purchasing an additional 21,000 shares during the last quarter. Telemetry Investments L.L.C. acquired a new stake in Clarus Therapeutics during the 3rd quarter worth about $240,000. UBS Group AG purchased a new stake in Clarus Therapeutics during the third quarter valued at about $206,000. Renaissance Technologies LLC acquired a new position in shares of Clarus Therapeutics in the first quarter worth about $52,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Clarus Therapeutics in the fourth quarter worth approximately $51,000. 19.50% of the stock is currently owned by institutional investors.

About Clarus Therapeutics (Get Rating)

Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with's FREE daily email newsletter.